Jef De Schutter
Impact in
- Oncology top 1%
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
Papers in
- Oncology 10
- Colorectal Cancer Treatments and Studies 10
- Co-authors
- Sabine Tejpar (7 shared papers)Wendy De Roock (7 shared papers)Bart Biesmans (5 shared papers)Eric Van Cutsem (5 shared papers)Jean–Luc Van Laethem (3 shared papers)Hubert H. Piessevaux (4 shared papers)Yves Humblet (3 shared papers)Marc Peeters (3 shared papers)
- Journals
- Clinical Cancer Research (3 papers)BMC Cancer (1 paper)Molecular Diagnosis & Therapy (1 paper)Journal of Clinical Oncology (1 paper)The Lancet Oncology (1 paper)
- Partner nations
- BelgiumUnited StatesGreece
In The Last Decade
Jef De Schutter
10 papers receiving 2.6k citations
Jef De Schutter's Hit Papers
Peers
Comparison fields: 5 of 46
- Oncology 1.7k
- Cancer Research 166
- Pathology and Forensic Medicine 62
- Otorhinolaryngology 13
- Pharmacology 17
Countries citing papers authored by Jef De Schutter
This map shows the geographic impact of Jef De Schutter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jef De Schutter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jef De Schutter more than expected).
Fields of papers citing papers by Jef De Schutter
This network shows the impact of papers produced by Jef De Schutter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jef De Schutter. The network helps show where Jef De Schutter may publish in the future.
Co-authors
The 25 scholars most cited alongside Jef De Schutter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Hit paper breakdown → | 2010 | 1821 |
| 2 | 2009 | 305 | |
| 3 | 2009 | 253 | |
| 4 | 2008 | 140 | |
| 5 | 2010 | 61 | |
| 6 | 2014 | 55 | |
| 7 | 2009 | 38 | |
| 8 | 2014 | 22 | |
| 9 | High Amphiregulin and Epiregulin expression in K-ras wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease | 2007 | 12 |
| 10 | PIK3CA mutations do not confer resistance to the EGFR-inhibitor cetuximab in chemorefractory metastatic colorectal cancer | 2009 | 1 |
About Jef De Schutter
Jef De Schutter is a scholar working on Oncology, Nuclear Energy and Engineering, Waste Management and Disposal, Infectious Diseases and Organic Chemistry, having authored 10 papers that have together received 2.7k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (10 papers). The work is most often cited by research in Oncology (1.7k citations), Cancer Research (166 citations), Pathology and Forensic Medicine (62 citations), Otorhinolaryngology (13 citations) and Pharmacology (17 citations). Jef De Schutter has collaborated with scholars based in Belgium, United States and Greece. Frequent co-authors include Sabine Tejpar, Wendy De Roock, Bart Biesmans, Eric Van Cutsem, Jean–Luc Van Laethem, Hubert H. Piessevaux, Yves Humblet, Marc Peeters, Gert De Hertogh and Steffen Fieuws. Their work appears in journals such as Clinical Cancer Research, BMC Cancer, Molecular Diagnosis & Therapy, Journal of Clinical Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.